Eye fluid biobank aims to unlock secrets of dry eye after transplant
NCT ID NCT04946721
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study collects eye fluid, cells, and blood samples from 150 adult cancer patients who have dry eye disease after a stem cell transplant (graft-versus-host disease). Researchers will analyze these samples to find risk factors, markers, and possible treatment targets. The goal is to better understand why this eye damage happens and how to prevent or treat it in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to new diagnostic tools and targeted treatments for dry eye disease in patients with graft-versus-host disease.
- What could go wrong
- This is an observational biobank study, not a treatment trial. It will not directly benefit participants and may not identify clear biomarkers or targets.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Geenebaum Cancer Center, University of Maryland Medical Center
RECRUITINGBaltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Dry eye gel may sharpen cataract surgery results
- New eye drops could bring relief to millions with chronic dry eye
- Could stem cell eye drops soothe dry eyes?
- Second plug may boost dry eye comfort
- New AI reads eye scans to diagnose dry eye instantly
- Popular diabetes drugs may ease dry eye, study suggests